Photodynamic therapy (PDT), as a globally accepted method for treating different forms of skin or mucosa disorders, requires efficient co-delivery of photosensitizer and corresponding therapeutic light. The adverse effects of...
DNA vaccination has emerged as an innovative approach for preventing and treating different diseases, including infectious diseases, cancer and autoimmune diseases. Although the results of ongoing clinical trials are promising, several limitations compromise the immunogenicity of these vaccines. Here, we present a novel immune strategy that combines transdermal immunization with skin electroporation to enhance the immunogenicity of the DNA vaccine. A flexible dissolving microneedle array (FDMNA) which contains 400 microneedles was developed. Each microneedle consists of a dissolving needle for delivering DNA vaccine and a flexible needle substrate for good tissue surface coverage. The FDMNA completely dissolve within 10 minutes after being inserted into the skin and transported the DNA into the immune-cell-rich epidermis and dermis layer. In vivo immunity tests were performed to observe the ability of FDMNA-mediated transdermal electroporation to induce immune response after the delivery of DNA. The result showed that, compared with the conventional immune method, the FDMNA induced nearly 16-fold higher levels of antibody immune response against ovalbumin in mice, providing sufficient immune protection. These findings suggest the potential utility of an FDMNA-based immune strategy for enhanced DNA vaccination
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.